Table 1 Baseline characteristics of all patients—responders and non-responders
From: Galectin-3 predicts response and outcomes after cardiac resynchronization therapy
All (N = 61) | Responders (N = 49) | Non-responders (N = 12) | p* | |
|---|---|---|---|---|
Age (years) | 61 ± 5 | 61 ± 5 | 64 ± 7 | 0.23 |
Female sex (%) | 17 (28%) | 14 (29%) | 3 (25%) | 0.80 |
CAD | 25 (41%) | 18 (37%) | 7 (58%) | 0.16 |
Gal-3 (ng/mL) | 17 ± 6 | 16 ± 6 | 19 ± 8 | 0.13 |
CRP (mg/L) | 7 ± 11 | 8 ± 12 | 6 ± 6 | 0.53 |
Baseline Minnesota | 30 ± 19 | 29 ± 18 | 34 ± 23 | 0.47 |
6 months Minnesota | 15 ± 14 | 15 ± 14 | 16 ± 18 | 0.90 |
Baseline NYHA class | ||||
NYHA II | 28 (46%) | 22 | 6 | 0.75 |
NYHA III | 33 (54%) | 27 | 6 | 0.75 |
6 months NYHA class | ||||
NYHA I | 36 (59%) | 36 | 0 | < 0.001 |
NYHA II | 25 (40%) | 13 | 12 | < 0.001 |
Baseline LVEF (%) | 27 ± 5 | 27 ± 6 | 27 ± 5 | 0.91 |
6 months LVEF (%) | 39 ± 8 | 41 ± 7 | 32 ± 7 | < 0.001 |
LVESV (mL/m2) | 72 ± 26 | 73 ± 26 | 69 ± 27 | 0.65 |
Presence of LGE | 26 (43%) | 17 (35%) | 9 (75%) | 0.01 |
LGE + number of segments | 2.2 ± 3.3 | 1.9 ± 3.4 | 3.5 ± 2.9 | 0.15 |
Percentage of LGE (%) | 11 ± 15 | 8 ± 13 | 22 ± 16 | 0.006 |
QRS before CRT (ms) | 163 ± 19 | 163 ± 21 | 165 ± 13 | 0.64 |
QRS after CRT (ms) | 135 ± 18 | 135 ± 20 | 136 ± 13 | 0.81 |
Selvester scoring (%) | 17 ± 9 | 17 ± 9 | 19 ± 10 | 0.63 |
Creatinine clearance (mL/min/1.73 m2) | 75 ± 23 | 77 ± 22 | 71 ± 27 | 0.40 |
Diabetes | 21 (34%) | 14 | 7 | 0.06 |